



## Aclaris Therapeutics Announces Poster Presentations at 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference

October 3, 2018

WAYNE, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:[ACRS](#)), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced poster presentations at the 2018 American Society for Dermatologic Surgery Annual Meeting in Phoenix, Arizona and the Fall Clinical Dermatology Conference in Las Vegas, Nevada. One poster is related to ESKATA<sup>®</sup> (hydrogen peroxide) topical solution, 40% (w/w), formerly known as "A-101," and two posters examine the impact of seborrheic keratoses (SKs) on patients and the need to improve communication between dermatologists/HCPs on SK treatment options.

- *The Hidden Impact of Seborrheic Keratoses: Analysis of a Psychometric Survey of an Ethnically-Diverse Cohort of U.S. Adults*
  - Authors: S. Xu, S. Wang and E. Estes
  - Presented at the 2018 American Society for Dermatologic Surgery Annual Meeting and Fall Clinical Dermatology Conference
- *An Open-Label Study of the Safety of HP40, a 40% (w/w) Hydrogen Peroxide Topical Solution, in Patients with Seborrheic Keratoses*
  - Authors: V. Callender, E. Frankel, J. Weiss, W. Werschler, C. Powala, B. Beger, E. Estes and S. Shanler
  - Presented at the 2018 Fall Clinical Dermatology Conference
- *Assessing Patient Concerns Regarding Seborrheic Keratoses on the Face: Comparison Against Other Cosmetic Concerns*
  - Authors: S. Xu and S. Wang
  - Presented at the 2018 Fall Clinical Dermatology Conference

### About ESKATA<sup>®</sup>

ESKATA (hydrogen peroxide) topical solution, 40% (w/w), is the first and only FDA-approved medication for the treatment of raised seborrheic keratosis (SKs).

### Important Safety Information and Approved Use

**ESKATA can cause serious side effects, including:**

- **Eye problems.** Eye problems can happen if ESKATA<sup>®</sup> (hydrogen peroxide) topical solution, 40% (w/w) gets into your eyes, including: ulcers or small holes in your eyes, scarring, redness, irritation, eyelid swelling, severe eye pain, and permanent eye injury, including blindness.
- **If ESKATA accidentally gets into your eyes, your healthcare provider will tell you to flush them well with water for 15 to 30 minutes. Your healthcare provider may send you to another healthcare provider if needed.**
- **Local skin reactions.** Skin reactions have happened in and around the treatment area after application of ESKATA. Severe skin reactions can include: breakdown of the outer layer of the skin (erosion), ulcers, blisters and scarring. Tell your healthcare provider if you have any skin reactions during treatment with ESKATA.

**The most common side effects of ESKATA include:** itching, stinging, crusting, swelling, redness and scaling.

Your healthcare provider will not apply another treatment of ESKATA if your treated area is still irritated from the previous treatment.

Tell your healthcare provider right away if ESKATA gets into your eyes, mouth or nose during application. ESKATA is for topical use on the skin only, and is not for use in your eyes, mouth or vagina.

These are not all the possible side effects of ESKATA.

### Approved Use for ESKATA

ESKATA is a prescription medicine used to treat seborrheic keratoses that are raised.

ESKATA is for use as an in-office treatment. ESKATA is applied by your healthcare provider and is not for use at home.

**You are encouraged to report negative side effects of prescription drugs to the FDA. Contact Aclaris Therapeutics, Inc. at 1-833-ACLARIS or 1-833-225-2747 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### About Seborrheic Keratoses

Seborrheic keratoses (SKs) are non-cancerous skin growths that are most commonly seen in middle-aged and older adults. SKs vary in color from flesh-colored to pink, yellow, gray, tan, brown, or black; can range in size from a millimeter to a few centimeters wide; and typically have a slightly

elevated, waxy or scaly appearance. The number of SKs tends to increase with advancing age. SKs frequently appear in highly visible locations, such as the face or neck, but can also appear anywhere on the body, except the palms, soles and mucous membranes.

#### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised SKs and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com) and follow Aclaris on *LinkedIn*.

#### **Cautionary Note Regarding Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris' commercialization of ESKATA and its ability to clear raised SKs with a low risk of scarring. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially Aclaris' reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris' Annual Report on Form 10-K for the year ended December 31, 2017 and other filings Aclaris makes with the SEC from time to time. These documents are available under the "Financial Reporting" section of the Investors page of Aclaris' website at <http://www.aclaristx.com>. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

#### **Contacts:**

Aclaris Contact  
Michael Tung, M.D.  
Senior Vice President  
Corporate Strategy/Investor Relations  
484-329-2140  
[mtung@aclariastx.com](mailto:mtung@aclariastx.com)

Media Contact  
Sara Baker  
Marina Maher Communications  
212-485-6836  
[sbaker@hellommc.com](mailto:sbaker@hellommc.com)



Source: Aclaris Therapeutics, Inc.